ArticleJournal of inflammation (London, England)2026
Montelukast suppresses NLRP3 inflammasome activation as a potential prophylactic agent against gout arthritis flares.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages.Immunobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGout arthritis (GA) flares are unexpected bouts of heat, swelling, and redness resulting in excruciating pain caused by monosodium urate (MSU) crystal deposition in the synovial joints. GA flare symptoms occur as a by-product of the inflammatory response as immune cells engulf MSU crystals in the joint. The NLRP3 inflammasome is the major source of the inflammatory response to MSU crystals; therefore, we hypothesize that prophylactic administration of agents that target the NLRP3 inflammasome could be used to suppress GA flares.
resultsWe previously performed a screen of 875 FDA-approved drugs to identify candidates that suppressed NLRP3 inflammasome activation without causing cytotoxicity in bone marrow-derived macrophages (BMDM). In this study, one of the candidates, montelukast, an anti-asthma drug, significantly suppressed Nlrp3- and Caspase-1-dependent IL-1β and IL-18 secretion by BMDM. Furthermore, in an MSU-induced mouse model of GA flares, treatment with montelukast mitigated pro-inflammatory cytokine/chemokine secretion, including inflammasome-dependent cytokines (IL-1β and IL-18), and edema.
conclusionsOverall, these data suggest montelukast is a robust suppressor of the NLRP3 inflammasome that could be repurposed as a prophylactic agent to mitigate GA flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.